Clinical Trials Sponsored by Xencor, Inc.

Total 35645 results

Xencor, Inc.

Terminated

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL

Diffuse Large-cell B-cell Lymphoma

Spain, United States, France
Xencor, Inc.

Recruiting

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Nonsquamous Non-small Cell Lung Cancer

United States
Xencor, Inc.

Recruiting

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Solid Tumors

United States
Xencor, Inc.

Recruiting

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Colorectal Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Ovarian Cancer, Epithelial | TNBC - Triple-Negative Breast Cancer | Renal Cell Carcinoma, Clear Cell | Melanoma Excluding Uveal Melanoma | Non-small Cell Lung Cancer, Squamous or...

United States
Xencor, Inc.

Recruiting

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Xencor, Inc.

Completed

Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

United States
Xencor, Inc.

Completed

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Xencor, Inc.

Recruiting

Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors

Testicular Germ Cell Tumor | Ovarian Cancer | Endometrial Cancer | Ovarian Germ Cell Tumor | Germ Cell Tumor

United States
Xencor, Inc.

Recruiting

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Psoriasis | Atopic Dermatitis

United States
Xencor, Inc.

Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Xencor, Inc.

Terminated

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States, Australia
Xencor, Inc.

Completed

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Allergic Rhinitis | Atopic Dermatitis | Allergic Conjunctivitis

United States
Xencor, Inc.
Parexel

Completed

XmAb5871 Bioavailability Study

Healthy Volunteers

United States
Xencor, Inc.
ICON plc

Terminated

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Merkel Cell Carcinoma

United States
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®18087 in Subjects With NET and GIST

Neuroendocrine Tumor | Gastrointestinal Neoplasm

United States
Xencor, Inc.
ICON plc

Recruiting

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Ovarian Cancer | Endometrial Cancer | Cervical Carcinoma | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Clear Cell Carcinoma

United States
Xencor, Inc.
ICON plc

Active, not recruiting

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions

United States
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Thymic Carcinoma | Thymoma | Non-small Cell Lung Carcinoma | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Cholangiocarcinoma | Breast Carcinoma | Fallopian Tube Carcinoma and other conditions

United States
Xencor, Inc.
ICON Clinical Research

Completed

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Acute Myelogenous Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | B-cell Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia, Blast Crisis

United States
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
Xencor, Inc.
ICON Clinical Research

Completed

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions

United States
Xencor, Inc.
Massachusetts General Hospital

Completed

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

IgG4-RD

United States
Xencor, Inc.
ICON Clinical Research

Completed

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

Safety in Healthy Volunteers

United States
Encora, Inc.

Recruiting

Upper Limb Tremor Reduction in Essential Tremor Patients (ULTRE)

Essential Tremor

United States
M.D. Anderson Cancer Center
Bayer; Xencor, Inc.

Withdrawn

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Colorectal Cancer | Colon Cancer | Rectum Cancer

United States
Xencor, Inc.
ICON Early Phase Services, LLC

Completed

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

Healthy Volunteers | Atopic Disease

United States
University of California, San Francisco
Xencor, Inc.

Active, not recruiting

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Metastatic Melanoma | Advanced Melanoma

United States
Memorial Sloan Kettering Cancer Center
Xencor, Inc.

Active, not recruiting

A Study of XmAb23104 in People With Sarcoma

Sarcoma

United States
TenNor Therapeutics Inc.

Completed

A Phase 1, Multiple Oral Administrations of TNP-2092 Capsules in Asymptomatic Healthy People With Helicobacter Pylori Infection

Helicobacter Pylori Infection
CinCor Pharma, Inc.

Completed

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (BrigHTN)

Resistant Hypertension

United States
TenNor Therapeutics Inc.

Completed

The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets

Helicobacter Pylori Infection

China
CinCor Pharma, Inc.

Completed

A Study of CIN-107 in Patients With Uncontrolled Hypertension (HALO)

Uncontrolled Hypertension

United States
TenNor Therapeutics Limited

Completed

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI)

Gram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial Infections

United States
Encore Vision, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia

Presbyopia

United States
Emory University
National Cancer Institute (NCI); Xencor, Inc.

Recruiting

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
Abramson Cancer Center at Penn Medicine
Xencor, Inc.

Active, not recruiting

XmAb20717 in Advanced Biliary Tract Cancers

Biliary Tract Cancer

United States
TenNor Therapeutics (Suzhou) Limited

Completed

Human Mass Balance and Biotransformation Study of [14C]TNP-2198

Helicobacter Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

Hyperammonemia

China
Encore Research Inc.
CoolSystems, Inc.

Completed

Cryopneumatic Device After Shoulder Surgeries

Shoulder Injuries | Shoulder Disease

Canada
TenNor Therapeutics (Suzhou) Limited

Completed

Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection

H.Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules

Hyperammonemia

China
TenNor Therapeutics (Suzhou) Limited

Completed

Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants

Helicobacter Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules

Helicobacter Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants

Helicobacter Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection

Helicobacter Pylori Infection

China
KGK Science Inc.
Gencor Pacific Limited

Completed

A Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants (14AWHG)

Body Weight

Canada
ReCor Medical, Inc.

Recruiting

The "Global Paradise System" Registry (GPS Registry)

Hypertension

Germany, Netherlands, Belgium, France, Monaco, Switzerland, United Kingdom
Xenon Pharmaceuticals Inc.

Terminated

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in Children

United States, Spain, Australia, Belgium, Italy
Xenon Pharmaceuticals Inc.

Completed

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Healthy Volunteers

United Kingdom

Clinical Trials Sponsored by Xencor, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations